Inflectra (Infliximab)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Inflectra (infliximab-dyyb) is a medication given as an intravenous (IV) infusion to treat the following conditions:
- Crohn’s disease
- Pediatric Crohn’s disease
- Ulcerative colitis
- Pediatric ulcerative colitis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
Fact Table
Formula
C6428H9912N1694O1987S46
License
US FDA, EMA
Bioavailability
Not applicable (IV administration)
Legal status
Prescription only (Rx)
Chemical Name
Infliximab
Elimination half-life
7.7-9.5 days
Dosage (Strength)
100 mg/vial
Pregnancy
Consult a doctor
Brands
Inflectra, Remicade, Renflexis, Avsola
Protein binding
Not reported
PubChem CID
16132230
MedlinePlus
a604005
ChEBI
CHEBI:7077
ATC code
L04AB02
DrugBank
DB00065
KEGG
D03207
Routes of administration
Intravenous (IV)
Directions
Your doctor will determine an appropriate treatment regimen for you, including Inflectra dosing. Inflectra will be administered via an IV infusion by a healthcare professional. Inform your doctor of any questions or concerns you may have about the medication.
Ingredients
The active ingredient in Inflectra is infliximab-dyyb.
Inactive ingredients include dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose.
Contraindications
Patients with moderate or severe heart failure should not receive Inflectra doses that exceed 5 mg per kg.
Additionally, patients who are allergic to infliximab or any of the other ingredients in Inflectra should not receive the medication.
Cautions
- Inflectra contains the following FDA Boxed Warning:
- The risk for serious infections that can result in hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens, is increased.
- Inflectra should be stopped if a patient develops a serious infection.
- Patients should receive a test for latent TB. If the test is positive, TB treatment should be initiated before starting Inflectra. All patients should be monitored for active TB during treatment, even if the latent TB test is negative.
- Children and adolescent patients treated with tumor necrosis factor (TNF) blockers such as infliximab have developed lymphoma and other malignancies; some have been fatal.
- Some patients treated with TNF blockers such as infliximab developed fatal hepatosplenic T-cell lymphoma (HSTCL). Almost all had received azathioprine or 6-mercaptopurine with a TNF blocker at or before diagnosis. Most of the cases were reported in patients with Crohn’s disease or ulcerative colitis, the majority of whom were adolescent or young adult males.
- Before you begin treatment with Inflectra, inform your doctor of:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Inflectra is associated with the following warnings and precautions:
- Serious infections, including invasive fungal infections
- Cancers
- Reactivation of hepatitis B virus
- Liver problems
- Heart failure
- Abnormal blood cell counts
- Hypersensitivity reactions, including anaphylaxis or serum sickness-like reactions
- Cardiovascular and cerebrovascular reactions, including heart attacks and arrhythmias
- Demyelinating disease
- Lupus-like syndrome
- Live vaccinations should not be administered to patients who are being treated with Inflectra.
Side Effects
Infections, infusion-related reactions, headache, and abdominal pain are common Inflectra side effects; however, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.
Ask your doctor about Inflectra.
Reference:
Inflectra. New York, NY: Pfizer Labs; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14558
-
Product Reviews
